Chemistry:Plozalizumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CCR2 |
| Clinical data | |
| Other names | hu1D9 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6490H10052N1736O2018S42 |
| Molar mass | 146032.46 g·mol−1 |
Plozalizumab (INN; hu1D9) is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.[1][2]
This drug was developed by Takeda Pharmaceuticals International Co.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Plozalizumab, American Medical Association.
- ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113". WHO Drug Information 29 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL113.pdf.
 |  |
